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For over 10 years, the European Vaccine Initiative (EVI; European Malaria Vaccine Initiative until 
2009) has contributed to the development of 24 malaria candidate vaccine antigens with 
13 vaccine candidates being advanced into Phase I clinical trials, two of which have been 
transitioned for further clinical development in sub-Saharan Africa. Since its inception the EVI 
organization has operated as a funding agency, but with a clear service-oriented strategy. The 
scientific successes and difficulties encountered during these years and how these efforts have 
led to standardization and harmonization in vaccine development through large-scale European 
consortia are discussed. In the future, the EVI will remain instrumental in the pharmaceutical 
and clinical development of vaccines against ‘diseases of poverty’ with a continued focus on 
malaria. EVI will continue to focus on funding and managing preclinical evaluation up to Phase I/II 
clinical trials and strengthening the vaccine-development infrastructure in Europe, albeit with a 
global orientation.
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EVI’s vaccine development have evolved over the 
last decade through the lessons we learned from 
our successes and failures. Finally, we will cast 
an eye to the future.
Past
The genesis of EMVI dates back to February 
1997 when the European Commission (EC)’s 
International Cooperation Research Programme 
with Developing Countries (INCO DC) sub-
mitted a proposal to the EU Member States. 
The proposal was fuelled by years of separated 
national and EC funding in the development of 
a malaria vaccine and a desire to improve com-
munication and delivery between these separate 
programs. At the outset, EMVI’s scope of opera-
tions addressed the translational gap between 
potential malaria vaccine candidates developed 
through basic science, and limited industrial 
production and early phase clinical trials (CTs). 
This niche, while being technically and legally 
complex, had traditionally been under financed.
Malaria was and is still among the most 
important parasitic cause of death and suffering 
today [101]. It is a major public health problem, 
particularly in sub-Saharan Africa, where the 
majority of the estimated annual cases of malaria 
Diseases of poverty (DoP) are a massive public 
health burden in many of the most resource-
constrained populations of the world [1]. In the 
context of the Millennium Development Goals, 
several governmental development agencies have 
committed themselves to reducing the burden of 
poverty related diseases, such as malaria. This 
commitment has been translated into support 
for academics and not-for-profit product devel-
opment partnerships (PDPs), through technical 
and operational support and day-to-day project 
management.
The European Vaccine Initiative (EVI) and 
its predecessor the European Malaria Vaccine 
Initiative (EMVI) has acted as a partner to bring 
together public development organizations and 
institutions involved in the design, develop-
ment and testing of novel vaccines. EVI not 
only directly funds the early stage development 
of vaccine candidates, but acts as a focal point 
for European and global vaccine research and 
development activities by coordinating numer-
ous externally funded consortia that are working 
towards accelerating the development of safe, 
effective and affordable vaccines.
This review, by addressing the past and cur-
rent portfolio, will illustrate how strategies of 
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occur. Each year worldwide, it is estimated that there are over 
250 million cases of malaria with over one million deaths. The 
overwhelming proportion (85–90%) of the malaria-attributable 
deaths occurs mainly in vulnerable populations of children under 
5 years and pregnant women living in the endemic areas of sub-
Saharan Africa [2–4]. Increased funding has supported the scale-up 
of malaria-control measures using the current control tools, such 
as insecticide-treated bed nets, procurement and distribution of 
anti-malarial drugs, early detection and treatment of malaria cases 
and vector control [5,101]. This has resulted in small but significant 
decrease in malaria incidence and prevalence in a limited number 
of countries where malaria is endemic.
There is no doubt that the key tool missing from the malaria 
control toolbox is an effective vaccine that would assist in the 
reduction or even elimination of the malaria disease [6]. The 
search for this tool has been ongoing for many decades and has 
included a myriad of vaccine concepts which until today have 
yielded only one partially efficacious (<50% efficacy) malaria 
vaccine, RTS,S, developed by a Malaria Vaccine Initiative (MVI) 
and GlaxoSmithKline Biologicals (GSK Bio; Rixensart, Belgium) 
collaborative effort [7–9]. This encouraging but less than satisfac-
tory result suggests the need for continued efforts to develop the 
next generation of highly efficacious malaria vaccines (>80% 
efficacy).
Three main scientific hurdles have impeded the successful 
development of an efficacious malaria vaccine:
•	 The enormous complexity of the parasite and its life cycle. We 
have limited knowledge of the interaction between the parasites 
and the human immune system. The para-
site has been able to coevolve with its host 
and has thus developed strategies to evade 
the host’s immune response;
•	 Extensive antigenic variation sensu 
stricto of the parasite;
•	 The different parasite lifecycle stages 
have unique antigen expression profiles.
Understanding the correlates of protec-
tion associated with the malaria infection 
and disease would support the development 
of an efficacious vaccine [10]. Although 
more knowledge has being gained from 
widespread and extensive studies and CTs 
in these areas in the last few years, there is 
still lack of full understanding of all these 
complex issues [6,11]. 
In comparison to other diseases where 
no correlates of protection are known (e.g., 
HIV) malaria infection can provide clini-
cal immunity. Previously published reviews 
have extensively discussed this naturally 
acquired immunity to malaria [12], which is 
acquired slowly after a number of exposures 
but has a relatively short duration. A better 
understanding of the host’s defense mecha-
nisms and the Plasmodium targets that pro-
vide protection from malaria disease will 
go a long away in the advancement of the 
knowledge required to develop a vaccine 
that will reproduce this natural immunity. 
Vaccine portfolio
EVI actively participated in the develop-
ment of the Malaria Vaccine Technology 
Roadmap (MVTR) [102] and since then, all 
EVI’s vaccine development efforts have fol-
lowed this recommended strategy. The road-
map contains the views and vision of malaria 
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experts toward the development and utilization of effective malaria 
vaccines. EVI supports malaria vaccine candidates that emerge from 
academic laboratories by sourcing and providing expertise and 
funding for production in line with Good Manufacturing Practice 
(GMP) and early clinical testing of the malaria vaccine candidates. 
EVI funding is targeted at diseases that may not be addressed by the 
pharmaceutical industry owing to likely poor economic returns. An 
overview of the EVI product portfolio and vaccine formulations is 
shown in Figure 1 and has been previously described [13].
Subunit vaccines
AMA1
In collaboration with the Biomedical Primate Research Centre 
(BPRC), two Phase Ia/Ib CTs of apical membrane antigen 1 (AMA1) 
adjuvanted in aluminum hydroxide, SEPPIC’s Montanide ISA 720 
and GSK’s AS02 were completed in Nijmegen, The Netherlands 
and in Bandiagara, Mali. In both CTs, the blood-stage vaccine for-
mulations showed acceptable safety and immunogenicity profiles. 
In Phase Ia, in vitro growth inhibition assay (GIA) showed levels of 
up to 80% antibody activity [14]. However, in the Phase Ib in Mali, 
although AMA1-specific IgG levels rose in vaccinees, the vaccine 
did not appreciably change GIA titers (Figure 2) [Thera M, Unpublished 
Data]. Thus, one of the conclusions of this clinical trial was that the 
polymorphisms in the AMA1 protein need to be addressed for the 
vaccine to show possible high efficacy in the field. This is discussed 
below in the section entitled AMA1-DiCo. These results were com-
parable to another AMA1 vaccine based on the 3D7 and FVO 
strains of Plasmodium falciparum, developed by National Institute 
of Allergy and Infectious Diseases, and the epidemiological data 
from Kenya [15,16]. The discontinuation of AMA1 is an example of 
project which did not fulfill the EVI go/no-go criteria. 
GMZ2
GMZ2 is a recombinant fusion protein of two P. falciparum pro-
teins, glutamate rich protein (GLURP) and merozoite surface 
protein 3 (MSP3), which EVI picked up in 2002 for develop-
ment [17]. Following a successful Phase Ia CT at the University 
of Tubingen (Germany) in 2006/2007, two subsequent Phase Ib 
CTs in African adults and children were conducted at the Albert 
Schweitzer Hospital, Lambaréné, Gabon [18,19]. Results from these 
CTs showed that the GMZ2 blood-stage vaccine candidate, three 
doses of which were administered 4 weeks apart, was well toler-
ated and induced satisfactory immune responses. Subjects who 
received the GMZ2 vaccine candidate showed a 1.4-fold (95% 
CI: 1.1–1.7) higher baseline-corrected anti-GMZ2 antibody levels 
and more GMZ2-specific memory B cells compared with the 
control group [19]. Unfortunately, the development of the GMZ2 
vaccine concept was hampered because the mechanism of its func-
tion could not be sufficiently elucidated by the read-out of CT 
samples through the Antibody Dependent Cellular Inhibition 
(ADCI) assays. The necessity to have standardized and harmo-
nized ADCI assays led to the development of the EC-funded 
OPTIMALVAC project (see below). 
Currently, a Phase IIb multicenter efficacy CT in children aged 
1–5 years is currently ongoing at four CT sites in sub-Saharan 
Africa. EVI has managed to transfer this project to the European 
and Developing Countries Clinical Trials Partnership (EDCTP), 
contributing by providing the current GMP batch. This CT is 
being conducted under the auspices of the EDCTP-funded GMZ2 
Consortium [103]. Results from this CT are awaited in 2011/2012.
Polyprotein
In 2002, EVI funded the assessment of the safety, immuno-
genicity and efficacy of two poxvirus malaria subunit vaccine 
candidates, FP9-PP and MVA-PP, which express the same poly-
protein and consist of six pre-erythrocytic antigens from P. fal-
ciparum. Although vaccine candidates were safe, the immune 
responses induced by vaccination were low compared with vac-
cine candidates of a similar nature. No efficacy was observed on 
sporozoite challenge. Definite reasons for these unsatisfactory 
results are unknown but possible explanations for the lack of 
immunogenicity in CTs have been recently outlined [20].
While there is now increasing agreement that multiple antigens 
and multiple stages will be required in a highly efficacious vac-
cine, this polyprotein approach, which was designed to broaden 
the immune responses induced by these vaccines, appear to have 
been unsuccessful. There is a suggestion that there may be a limit 
to the size of the inserts (in this case polyprotein transgene) that 
will be immunogenic in humans. 
Following the evaluation of these results, other vaccine-admin-
istration strategies, including the mixture of various single com-
ponent vaccines are now being tried as alternatives in current 
preclinical development of these groups of vectored vaccines. 
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MSP3
In 1998, the safety and immunogenicity of the antigen MSP3 pro-
duced as a long synthetic peptide (LSP) was tested in a Phase Ia 
CT. MSP3-LSP was formulated in two adjuvants, aluminum 
hydroxyde and Montanide ISA 720. There were unacceptable 
local reactions with the MSP3-LSP plus Montanide ISA 720 
after the second dose, which led to the withdrawal of some vol-
unteers. MSP3-LSP was immunogenic with both adjuvants but 
the unacceptable reactogenicity with the Montanide adjuvant 
led to the decision not to take the MSP3-LSP plus Montanide 
ISA 720 formulation further in planned CTs in Africa. A recent 
review has shown that malaria antigens as LSP are immunogenic 
in human CTs [21].
The collapse of the small and medium-sized enterprise responsi-
ble for GMP production of MSP-LSP (Dictagene S.A., Lausanne, 
Switzerland) led to the discontinuation of EVI funding for this 
project. However, further development of this vaccine candidate 
was taken up by AMANET/Institut Pasteur (Paris, France) and 
recent publications from the Centre National pour la Recherche 
et la Formation sur le Paludisme (CNRFP, Burkina Faso) and 
the Institut Pasteur show that progress has been made with this 
vaccine formulated in aluminum hydroxide [22,23]. In a limited-
size CT in children at 1–2 years of age, the incidence of malaria 
was lower in the MSP3 vaccinated children than in the control 
group, at 60 days after the last immunization. Those preliminary 
results need to be confirmed in a larger size CT but support the 
development of a blood-stage vaccine for preventing malaria.
EURHAVAC
From the lessons which were learned during the initial malaria vac-
cine development efforts (1998–2004), the European Network for 
Harmonisation of Malaria Vaccine Development (EURHAVAC), 
an EC 6th Framework Programme (FP6), was initiated. In col-
laboration with the WHO and the malaria vaccine community, 
the consortium focused on the formulation of decision-making 
processes for supporting the development of more innovative 
and rationale-based vaccines that are carefully guided through 
design and production into CTs. In Table 1 an example is given 
of antigen assessment criteria for evaluation of potential malaria 
vaccine candidate antigen concepts prior to development. These 
go/no-go criteria are still used by the EVI. Four other categories 
of assessment criteria were formulated: vaccine rationale, vaccine 
delivery systems and formulation, antigen/vaccine production 
processes, and antigen and vaccine characterization. These criteria 
are available on the internet [104]. 
Present
During the last decade, EVI has demonstrated its ability to 
establish and maintain an enabling environment that allows 
malaria vaccine development: it has funded 29 different vaccine 
Geels, Imoukhuede, Imbault et al.
Table 1. Assessment criteria for development of malaria vaccines: rationale for choice of antigen.
Attribute Criteria Comments
Stage of parasite Must be defined
Accessibility Specific antibodies must react with intact 
parasites by IFA
Functionality Should have functional assay Examples: erythrocyte binding, 
growth inhibition
In vivo protection after immunization with the 
vaccine antigen in an animal model
Demonstration is a strong justification for 
further development
In vitro inhibition Demonstration bolsters rationale for further 
development
Sequence diversity Must be characterized
Rationale for development plan must be presented
Arguments can be mounted for 
promise of both high- and low-
diversity antigens
Parasite dependence on antigen Must be characterized
Rationale for development plan must be presented
Parasite dependence on antigen 
best determined by ability (or 
inability) to knock out gene
Epidemiological association of antigen with 
protection
Available information must be present Presence is encouraging, but subject 
to the fallacy of interpretation of 
association as causality
Also consider vaccine potential that 
does not mimic nature
Antigenicity Must react with antibodies or cells of infected 
and/or immunized individuals
Pre-existing clinical data Must be considered in development plan Data from any prior trials must be 
provided, if possible
IFA: Immunofluorescence assay. 
Reproduced with permission from [104].
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adjuvant/delivery formulations resulting in 13 vaccine candidates 
advanced into Phase I CTs. 
The current EVI product portfolio currently comprises the 
following vaccines.
Subunit vaccines
AMA1-DiCo
Using knowledge generated from earlier CTs indicating allelic 
breakthrough, three artificial AMA1 sequences with a very high 
coverage of naturally occurring alleles were designed (on aver-
age >97%). This diversity covering (DiCo) approach is currently 
under development by a continuing EVI–BPRC collaboration 
and is expected to overcome the polymorphisms found in nature. 
For the AMA1-DiCo vaccine candidate, process development and 
adjuvant selection have been completed and preparations for a 
Phase Ia and Ib CTs in European and African adults are ongoing. 
During the development of the AMA1 concept with differ-
ent adjuvants (aluminum hydroxyde, Montanide ISA 720 and 
ASO2), it became evident that divergence existed with respect 
to vaccine safety evaluation. These developments illustrated the 
necessity to further standardize vaccine safety evaluation. A 
second important lesson from the development of the AMA1 
concepts was the difficulty in comparing the clinical settings in 
which the different AMA1 formulations were previously tested 
in the world by, for example, US groups and Australian groups 
[24]. The collaboration of the Malaria Vaccine Funders Group 
(MVFG)  led to the selection of exactly the same CT site in 
Mali for the BPRC CT and further necessitated the need for 
harmonization of clinical development strategy for malaria vac-
cine candidates developed in Europe, including definition of the 
go/no go criteria for entering Phase Ia CTs, definition of safety 
evaluation criteria and definition of immunological evaluation 
criteria [25].
P27A
EVI supports one innovative peptide blood-stage vaccine candi-
dates against malaria. The first approach comes from Corradin 
and collaborators who have demonstrated that a bioinformatics/
chemical synthesis approach can lead to the rapid identification of 
molecules that target biologically active antibodies. They selected 
several a-helical coiled-coil domains of the proteins predicted to 
be present in the parasite erythrocytic stage [26]. A novel malaria 
blood-stage vaccine candidate, the P. falciparum 3D7 protein 
PFF0165c, also known as P27A, was identified by this process 
[27]. Since 2010, EVI has supported the preclinical assessment of 
this antigen. Process development and GMP production of this 
vaccine concept are currently ongoing.
JAIVAC-1
The malaria vaccine candidate JAIVAC-1 of the International 
Centre for Genetic Engineering and Biotechnology, (ICGEB 
[India, New Delhi]), is currently undergoing a proof-of-concept 
Phase I safety and immunogenicity CT. This vaccine is a com-
bination of amino-terminal, conserved, cysteine-rich region of 
the 175-kDa P. falciparum erythrocyte-binding antigen EBA175 
and 19-kDa MSP-1, adjuvanted in Montanide ISA 720 [28,29]. 
Enrolment and vaccinations have has been completed and the 
CT is expected to end in the fourth quarter of the calendar year 
(Q4) 2011.
In recent years, it has become widely accepted within the 
malaria vaccine community that deploying Montanide ISA 720 as 
an adjuvant in malaria vaccine formulations for children in Africa 
will be problematic. In parallel to the ongoing proof-of-concept 
Phase I CT, ICGEB has made considerable efforts to provide a 
suitable adjuvant for enhancement of the safety and immunoge-
nicity of the JAIVAC-1 vaccine. Subsequently, collaboration is 
ongoing with the Infectious Disease Research Institute (IDRI) 
and the TRANSVAC consortium to meet this objective.
Vectored vaccines
The CSVAC project focuses on the development of an experimen-
tal circumsporozoite protein vectored vaccine against malaria, 
prepared using the chimpanzee adenovirus 63 vector (ChAd63) 
[30]. This pre-erythrocytic vaccine candidate is currently undergo-
ing GMP production and a Phase I CT is planned to start in Q4 
2011. The ChAd63 vector has several advantages: 
•	 Lack of significant pre-existing immunity to ChAd63 in most 
human populations [Hill A, Unpublished Data]; 
•	 High yield of viral particles in a GMP manufacture construct; 
•	 High immunogenicity of ChAd63 recombinants in animal mod-
els, matching or exceeding that of the potent Ad5 recombinant 
vector [31];
•	 Good safety and encouraging immunogenicity in an ongoing 
Phase I CT of this vector with another malaria insert 
(ME-TRAP).
The rationale to develop this vector in combination with CSP 
while the RTS,S concept is already in late-stage development is 
built upon extensive preclinical data in murine models that clearly 
show that very high levels of CD8 T cell are required to provide 
protective efficacy at the liver stage of infection with the CSP 
antigen. RTS,S induces minimal detectable CD8 T-cell response 
in humans [32] and first- and second-generation vectored vaccines, 
such as DNA-MVA produced only modest CD8 T-cell immuno-
genicity in humans [33]. However, new simian adenovirus vectors 
induce potent CD8 T cells in humans against other malaria anti-
gens in Phase I/II CTs [34,35] and so there is a strong prospect that 
this new prime–boost strategy will be more effective with CSP.
The clinical development of viral vectored malaria vaccine can-
didates is also funded by an EDCTP grant to the EVI-coordinated 
Malaria Vectored Vaccines Consortium (MVVC) [105]. This 
4-year project was set up with the aim of integrating capacity-
building and networking in the design and conduct of Phase I and 
II CTs of viral-vectored malaria vaccine candidates in East and 
West African adults, children and infants. The research objective 
of the MVVC is to demonstrate safety and immuno genicity of an 
adenoviral vector modified Vaccinia Ankara (MVA) virus prime–
boost regime, encoding ME-TRAP in adults and young children 
in sub-Saharan Africa. The pre-erythrocytic vaccine candidates to 
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be evaluated are ChAd63 ME-TRAP and MVA ME-TRAP. Age 
de-escalating assessment of the safety and immunogenicity of this 
new prime–boost regime in protection against clinical malaria in 
adults, 2–6 year-old and 5–17-month-old children has started in 
two African CT sites located in East and West Africa and evalua-
tion of efficacy will be conducted in three other African CT sites.
As predicted from preclinical studies, the preliminary results from 
the ongoing CTs show that the heterologous prime–boost malaria 
vaccine regimens ChAd63 ME-TRAP and MVA ME-TRAP are 
safe and considerably more immunogenic than previous vectored 
vaccines in semi-immune Gambian adults and children aged 
2–6 years. Results from efficacy CTs are expected in Q4 2013. 
European Malaria Vaccine Development Association
In addition to directly supporting malaria vaccine activities, in 
2006 EVI along with 19 other scientific institutions in Europe 
and Africa successfully applied to the EC FP6 for a grant for the 
development of malaria vaccine candidates. EVI plays a lead-
ing role as the coordinator of this integrated project, referred 
to as the European Malaria Vaccine Development Association 
(EMVDA) [106], run in partnership with all European institu-
tions developing blood-stage malaria vaccines. A scientific and 
technological structure has been established to move malaria 
vaccine candidates from preclinical to early phase clinical 
development. EMVDA has provided a platform for scientists to 
compare the expression of the antigens in different vector-based 
systems, or the enhancement of the immunogenicity by differ-
ent adjuvants. All the partners agreed to use the same stringent 
go/no-go criteria, to decide which formulation will be then tested 
in humans. These criteria include continuous evaluation as to 
whether scientific, evidence-based rationales (efficacy, technical 
and regulatory feasibility) are present that justify further devel-
opment [36]. This strategy ensures that resources are allocated in 
the most efficient way to move the most promising vaccine can-
didates into GMP production and Phase I CT. Currently, four 
vaccine candidates have been selected: MSP1 prime–boost with 
ChAd63 + MVA and AMA1 prime–boost with ChAd63 + MVA 
(both University of Oxford, UK), full-length MSP1 (Heidelberg 
University, Germany), SR11.1 (Centre Hospitalier Universitaire 
Vaudois, Switzerland). To select and promote development of 
the most promising vaccine candidates, EMVDA has united 
the capabilities of small and medium-sized enterprises, major 
European malaria vaccine research centers, EVI, and African 
partners already linked through the AMANET as a consortium.
The EMVDA project is organized into six areas:
•	 Candidate antigens;
•	 Platforms and adjuvants;
•	 Vaccine development including assays for vaccine evaluation;
•	 Demonstration activities including GMP production and 
Phase I CTs;
•	 Training, integration and partnership activities;
•	 Management activities comprising both consortium management 
and product-development management.
The structure of EMVDA was based on lessons learned from 
the EURHAVAC consortium [25]. The EMVDA consortium 
actively cooperates with other global stakeholders in the field of 
malaria vaccine development, and in particular WHO. It par-
ticipates in, and contributes to, agreed global coordination and 
harmonization efforts [102]. 
Vaccine harmonization, coordination & capacity 
strengthening
Every vaccine being developed has its own technical and societal 
characteristics that renders the vaccine unique. However, to avoid 
loss of, and contribute to, harmonization of critical technological 
knowledge, the transfer of this knowledge needs to be secured, 
both within and outside the EU. To this end, EVI has coordinated 
the research networks EURHAVAC, PHARVAT, INYVAX and 
OPTIMALVAC, which are specific EC FP6-funded actions on 
harmonization of vaccine development in Europe and beyond. 
PHARVAT aims to generate a harmonized procedure to permit 
preclinical selection of vaccine adjuvants throughout Europe and 
will finish by the end of 2011. The overall goal of OPTIMALVAC 
is to develop harmonized assays for parasite-antigen recognition, 
antibody and cell-dependent parasite inhibition and cell-mediated 
immune-response assays. The consortium currently focuses on 
the development, dissemination and implementation of Standard 
Operating Procedures for the conduct of key assays to Good 
Laboratory Practice level. To meet all of this, the consortium has 
set its goals on the development and sharing of reference prepara-
tions and common reagents for ADCI, ELISA, immunofluores-
cence assay (IFA) and GIA [37]. Furthermore, OPTIMALVAC is 
establishing a web-based tool for communication and tracking of 
activities. Consistent, reproducible and comparable intra- and inter-
laboratory performance and increased accuracy and precision of 
assay data will strengthen the quality of the vaccine development 
and CTs and will generate greater confidence in the evaluation of 
potential malaria-vaccine candidates.
The overall goal of INYVAX is to improve access to vac-
cine technology spanning across different diseases by develop-
ing knowledge-based platforms, that is, for antigen discovery 
optimization of delivery systems and formulations. In addition, 
INYVAX is developing safety standards in prelicensure CTs of 
vaccines against DoP, allowing meta-ana lysis of the safety of 
similar vaccine approaches [38]. Finally, it provides funding for 
advanced training in vaccinology for vaccine researchers on the 
ADVAC course.
When EVI funds the development of vaccine candidates, it 
ensures training and assurance in Good Clinical Practice (GCP), 
and in project management, including training of personnel from 
the endemic areas. In addition, over the 13 years of its existence, 
EVI has supported 12 PhD students through its own grants or 
via EC-funded consortia. 
TRANSVAC
Europe’s position as the leader in different fields of vaccinology 
is now hampered by the decision of European governments, 
for economic reasons, to withdraw from funding state-owned 
Geels, Imoukhuede, Imbault et al.
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vaccine production facilities [39]. This withdrawal of funding 
is likely to slow down innovation in vaccine research, having 
an immediate effect on the pool of knowledge and competen-
cies, and increasing the degree of fragmentation of know-how 
and facilities. Infections do not stop at borders: the vaccine 
industry is global, but in Europe vaccine research institutes are 
national. In the current world economic and political situation 
there is an obvious absence of a European agenda on vaccine 
R&D both in terms of production and number of workers. In 
addition, there is a lack of synergy between the private and 
the public sector, and lack of commonly defined strategies by 
the EU Member States’ public sectors, with a limited counter-
weight to the heavy policy influence of the private sector. The 
European vaccine development community needs to establish 
an efficient, sustainable collaborative infrastructure based on 
shared visions and goals in order to address these challenges. 
Through EVI, TRANSVAC, a collaborative infrastructure 
project funded under the EC FP7, has emerged as a joint effort 
of leading European groups in the field of vaccine development 
to enhance coordination between vaccine R&D groups, assay 
developers and vaccine producers in Europe, and to propose a 
European road map for vaccine R&D.
TRANSVAC aims to accelerate the development of promising 
vaccine candidates by bridging the gap between bench research 
and CTs. To reach this goal, TRANSVAC carries out activities 
at various levels: 
•	 Research: fostering the development of experimental vaccines 
through improving the use of (molecular) assays, standardized 
reagents, adjuvants, animal models, and antigen and cell bank 
production;
•	 Networking: the consortium provides training in vaccine devel-
opment, harmonizing assays and microarrays, and optimal 
animal models. Activities here include a modular course on 
concepts in vaccine development as well as a series of workshops 
on animal models;
•	 Services: providing researchers with free access to adjuvant for-
mulation, animal models, standards and global analyses (e.g., 
microarrays). These services are at the core of the consortium 
and are free of charge to European vaccine R&D groups.
Through a peer-reviewed competitive process, European groups 
working in vaccine development may apply to benefit from the 
expertise, reagents and facilities of the TRANSVAC consortium. 
TRANSVAC’s vaccine development services are not linked to 
any particular type of disease. Currently, 11 proposals have been 
funded through TRANSVAC services and they can be found on 
the TRANSVAC website [107]. 
Future
Lessons learned from malaria vaccine development
The EVI has evolved considerably over the last few years. In 
the past, EVI has focused on the translation of basic vaccine 
research, with a goal to bridge the gap between bench and bed-
side through the validation of vaccine concepts and supporting 
the transition of academic knowledge into products within a 
regulatory framework. However, when innovation in research is 
not stimulated enough, then very few new vaccine candidates are 
available for proof-of-concept, that is, the EVI pipeline is dry-
ing up. In Europe it has classically been the role of the national 
research councils and of the Directorate General (DG) research 
of the EC to fund innovation. The risk associated with this has 
become evident over the last few years and to mitigate this risk 
it has been decided by the EVI Scientific Advisory Committee 
to broaden the strategy and commence funding of vaccine con-
cepts and technical platforms that are still in the discovery phase 
of development. The vaccines developed by EVI must be safe, 
efficacious and affordable. 
Safety
EVI has been facing several safety challenges when developing 
new antigens with new adjuvants, during toxicological stud-
ies (GMZ2 with DDA-TDB) [108] or during Phase I CTs [14]. 
Recommendation is now made to the scientists to first enhance 
the antigenicity of their molecules and to preferably consider 
already validated adjuvants for CTs. Standardized assessment of 
safety during CTs is being implemented following the INYVAX 
guidelines, developed by the Brighton Collaboration.
Efficacy
An effective malaria vaccine is possible, as shown by the develop-
ment of the partially efficacious RTS,S vaccine by GSK Bio [40]. 
In 2010, more than a dozen vaccines had reached the stage of 
Phase II CTs, nine were tested in human challenge CTs, three of 
them in partnership with EVI, five vaccines were in Phase IIb, two 
of them in partnership with EVI [108]. In a Phase I CT in children, 
the use of the MSP3 vaccine has demonstrated a reduction of 
the incidence of malaria episodes [22]. There are no correlates of 
protection available; therefore human challenge CTs should be 
an important gateway in the screening of new antigens. Through 
EMVDA, EVI is participating in the development of blood-stage 
human challenge model. 
Affordability
The choice of producing the subunit antigens as long synthetic 
peptide vaccines and not as recombinant vaccines was decided 
because of the low price of GMP production. After several tech-
nical challenges, MSP3 is in Phase II CTs, and P27A will be also 
a synthetic vaccine. The high cost of production of the RTS,S 
vaccine is mainly due to the complex adjuvant that is needed to 
elicit immune response and protection. EVI will investigate new 
approaches to enhance the immunogenicity of the antigens, thus 
supporting new delivery and presentation systems.
Accelerating the vaccine development
EVI has proven through its development of the GMZ2 and 
MSP3 blood-stage vaccine candidates that it can facilitate vac-
cine development through to Phase II clinical testing. Both con-
cepts were deemed safe and tested in dose-finding CTs within 
3–6 years.
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Together with its partners, EVI has witnessed the concerted 
evolution from the classical way of conducting Phase Ia CTs in 
Europe and subsequent Phase Ib CTs in Africa towards multi-
center combined Phase I CTs. This trend has reduced both lead 
times and costs. Simultaneously, human challenge studies have 
matured and proved their value. One of the next key steps is 
the transfer and establishment of the human challenge model to 
clinical research centers in sub-Saharan Africa. 
However, to date, the subunit malaria vaccine candidates have 
not yielded the aspired high vaccine efficacy. This has fuelled the 
development of testing of vaccination with whole-cell prepara-
tions, either as irradiated, live-attenuated cells or as a low dos-
age of blood-stage parasites [41–43]. Once injected, the sporozoite 
stage of the malaria parasite confer long-lasting, sterile protection 
against infection, providing a benchmark for vaccine development 
[44]. Furthermore, the discovery of genetically engineered parasite 
strains that are fully attenuated during the liver-stage infection 
and confer sterile protection in animal malaria models [42] sup-
port the development of a live-attenuated sporozoite vaccine for 
P. falciparum and its accelerated safety and efficacy testing in 
malaria challenge models and in malaria endemic areas represents 
a significant step forward in malaria vaccine development.
Neglected tropical diseases
The WHO estimates that more than 1 billion people living 
on <US$2/day are affected by at least one ‘neglected tropi-
cal disease’ (NTD) [109]. NTDs are flourishing in low-income 
populations and are an obstacle for the achievement of health in 
the Millennium Development Goals. Their significance to pub-
lic health and economies is obvious and grouping them under 
one term can ensure concerted and focused actions for govern-
ments, non-governmental organizations, donors, industry and 
international agencies. 
For vaccine development against the three major DoPs: HIV, 
TB and malaria, highly focused product development initiatives 
already exist. Relative to other NTDs, which are not yet fully on 
the agenda of international or governmental development agen-
cies despite their impact on low-income populations, these three 
diseases have attracted more funds than ever before. This has 
indeed created unprecedented pipelines with promising vaccine 
candidates for HIV/AIDS, TB and malaria. The pitfall would 
be to remove these three diseases, together still causing a lot of 
disease and death, from the list of neglected infectious diseases. 
Keeping the pipeline filled and bringing these vaccines success-
fully to the market at affordable prices will still demand huge 
amounts of public and philanthropic funding while industry is 
focusing on more profitable markets for survival. At the same 
time it would be tragic if this funding would come at the cost of 
sufficient financing for R&D of the other NTDs, which some 
therefore term the ‘really neglected’ tropical diseases. It is in this 
niche that EVI will be supporting the development of vaccines. 
Vaccines are key assets in the fight against DoP, and therefore, 
accelerated development of safe and efficacious vaccines repre-
sents a top priority and should count on sufficient, predictable 
and sustainable funding at national and international level.
According to WHO, NTDs are mainly parasitic and viral dis-
eases, that is, buruli ulcer, Chagas disease (American trypano-
somiasis), cysticercosis, dracunculiasis (guinea-worm disease), 
echinococcosis, leishmaniasis, leprosy, lymphatic filariasis and 
schistosomiasis. For treatment of these diseases, a very limited 
array of drugs exists, most often to be taken over a long period of 
time and with serious side-effects. An effective vaccine does not 
yet exist for any of the NTDs. 
EVI intends to support the development of vaccines against 
NTDs in the same way as it has done within the malaria field. 
First, a shared vision and strategy among the most relevant inter-
national experts and stakeholders from disease endemic countries 
will be developed. Once the goals are set, EVI will focus on antigen 
selection, assay standardization and validation, sustainable process 
development and manufacturing in accordance with international 
quality requirements. Clinical and regulatory strategies will be 
developed to ensure coherent and consistent development based 
on strong rationale and harmonization of the evaluation criteria 
used for safety, immunogenicity and protection.
Trends in funding
Funding for malaria and NTDs vaccine research comes from a 
variety of sources: governmental donors, multilateral organiza-
tions (WHO, World Bank and EC), philanthropic foundations 
and industry.
It is difficult to establish a clear picture of the total amount of 
resources invested in malaria vaccine research. First, one cannot 
get a good insight into the total investments made by the phar-
maceutical industry in malaria vaccine R&D. Second, because 
malaria vaccine development builds on fundamental research 
findings from various disciplines. Fundamental research is coor-
dinated through national research councils and financed with 
national public funds, resulting in a variety of national funding 
streams and incentives, thus fragmenting the research landscape. 
Funding for malaria vaccine research has been on the rise 
since the mid-1990s. From an unknown proportion of a total of 
US$84 million for malaria R&D in 1993 (probably ~US$20 mil-
lion extrapolated from later figures for vaccine development), 
going up to US$79 million for malaria vaccine R&D in 2004 
[110] and, despite the global financial crisis, rising further to 
US$195.8 million in 2009 [111]. However, recent global economic 
and financial developments indicate that the impact of the finan-
cial crisis is leading to serious fiscal constraints. As a result many 
donors are drastically cutting budgets for international devel-
opment cooperation and requiring that funding should serve 
national interests first [39]. 
It is important to see the current malaria vaccine funding in 
light of current progress in malaria vaccine development. The 
results of CTs with the RTS,S pre-erythrocytic malaria vaccine, 
developed by GSK Bio and funded by the Bill & Melinda Gates 
Foundation, via the MVI, have generated renewed attention for 
malaria vaccines and have reinvigorated the conviction of scientists 
that a protective malaria vaccine is feasible.
In a recent article it was concluded that the RTS,S vaccine 
will only be partially efficacious and the real health impact of 
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this first-generation malaria vaccine still needs to be assessed [40]. 
Although RTS,S represents an important milestone in malaria vac-
cinology, the funding needed for Phase IV of RTS,S also gener-
ates a difficult conundrum for the allocation of the existing scarce 
resources for malaria vaccine R&D: continuation and even increase 
of investments to develop a partially efficacious vaccine or invest-
ment in R&D of second-generation and other types of malaria vac-
cines that can be brought to the market by (other) industry players. 
Putting ‘all eggs in one basket’ might be an unwise choice for the 
future of malaria vaccine development. Funding of a diversity of 
malaria vaccines might be the soundest strategy to defeat such a 
‘shrewd’ organism as the malaria parasite, but this comes at a cost. 
Learning from experience and analyzing the latest global devel-
opments, four different perspectives are feeding into the EVI 
funding strategy which will focus on malaria and DoP: 
•	 Combining public and private efforts; 
•	 Convergence of national and international research objectives; 
•	 Assembling a research infrastructure for long-term objectives;
•	 Enabling serendipity by multidisciplinary and cross-disease 
fertilization.
International collaboration
EVI has signed separate memorandums of understanding with 
the US Agency for International Development Malaria Vaccine 
Development Program, PATH Malaria Vaccine Initiative, 
Tuberculosis Vaccine Initiative, Brighton Collaboration 
Foundation and Malaria Vaccine Development Program and a 
memorandum of intent WHO. EVI is an active member of the 
MVFG, which was created in 2001, and has developed a global 
portfolio review and the MVTR [102]. Finally, the collaboration 
with the private sector must be strengthened, and the TRANSVAC 
project will play a major role in identifying and prioritising poten-
tial areas of collaboration with pharmaceutical industry, mainly 
the European Vaccine Manufacturers. Special attention will be 
paid to collaboration with the Developing Countries Vaccine 
Manufacturers Network (DCVMN). International cooperation 
is the only way the leverage of knowledge and resources can be 
achieved to combat DoP.
Three scientific priorities of a sustainable vaccine 
development platform
To be successful in the future in the development of new vaccines 
for malaria and DoPs, the focus of the EVI will be on what it calls 
the three scientific priorities of sustainable vaccine development 
platform. These three pillars are:
•	 Translational vaccine research;
•	 Knowledge sharing;
•	 Harmonization of vaccine research efforts.
Translational research
For the vaccine pipeline to be continuously filled it is impera-
tive that creativity and innovation is fostered while remaining 
focused on the proof of concept, that is. early stages of clinical 
development, to ensure the realization of promising vaccine can-
didates that have the best possible chance of success. Although 
the basic science part of a vaccine is at the core of the concept, 
minimal levels of quality assurance, process development (ana-
lytical and process qualification), regulatory aspects and market 
entry should be taken into account in order to mitigate costly, 
late-stage changes during development. To this end, EVI facili-
tates technology transfer of production of new vaccine candidates 
to qualified producers. EVI works toward sustainability of its 
adjuvant platform, including access to new adjuvants and vaccine 
formulation, and encourages studies for better understanding 
of the mechanisms of adjuvant action. Likewise, it is necessary 
to keep on supporting innovative technology to improve the 
delivery of antigens (e.g., alternative routes of administration, 
improvement of heat stability and increase in yield). Finally, it 
is important to maintain a dialogue with policy makers through 
consultative working groups on specific scientific, regulatory 
or technical questions and sustained mobilization of funds for 
translational vaccine research. 
Knowledge sharing
Next to ensuring that vaccine innovation can thrive, it is abso-
lutely essential that knowledge created within vaccine develop-
ment is disseminated appropriately. EVI aims to secure sharing 
of vaccine knowledge by the training of vaccine developers. In 
this context, EVI is expecting to set up a fellowship program 
for scientists interested in management of vaccine development. 
Additionally, EVI will continue to participate in training pro-
grams for project/program management and to conduct inter-
national workshops on scientific topics of relevance to vaccine 
development for DoP.
Harmonization
The harmonization of immuno-assays and clinical protocol 
development are key elements in generating comparative and 
reproducible results. The key focus should be that assay devel-
opment is in line with new vaccine targets and provides real 
improvements in evaluating immune responses in target popula-
tions. Finally, and probably the most difficult, is that through 
harmonization we can encourage the development of biomarkers 
and other surrogates of protection.
A key development is demonstrating through TRANSVAC 
the importance of the integration of vaccine development activi-
ties in Europe, and the optimization of resources allocated by the 
public sector to the R&D of vaccines. TRANSVAC will explore 
the genesis of a European Vaccine Development Infrastructure. 
TRANSVAC will launch a special call in 2012 inviting applica-
tions for external institutions to join and further complement and 
strengthen the consortium, if they are able to bring relevant expe-
rience/expertise for mutual benefit into TRANSVAC. Through 
TRANSVAC, a working group with pharmaceutical industry 
will be put in place in order to identify the synergies between 
private and public sector. This assessment will drive the process 
for designing the strategy of the European Vaccine Development 
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Infrastructure, which should be created in continuation of the EVI, 
along with other stakeholders.
Expert commentary & five-year view
EVI’s scope of operation in the vaccine development pipeline is 
in the gap between vaccine candidates for DoP developed via 
basic science and early phase clinical development. EVI has sup-
ported both financially and technically, all vaccine development 
activities through:
•	 Antigen selection, assay standardization and validation, devel-
opment of challenge models and development of CT protocols 
and finally the manufacture of promising malaria vaccine 
candidates; 
•	 Clinical and regulatory development based on strong rationale 
and harmonization of the evaluation criteria used for safety, 
immunogenicity and protection; 
•	 The performance of early phase clinical development by fund-
ing Phase I and when relevant, validated Phase II CTs of these 
vaccines in a limited number of CT centers in Europe.
In the next 5–10 years, EVI will address the current major gaps 
in vaccine development by;
•	 Broadening the funding to vaccines targeted at all DoP to 
ensure a pipeline as diverse as possible;
•	 Extending the initiative focus on P. falciparum to other Plasmo-
dium species;
•	 Strengthening the vaccine R&D infrastructure in Europe 
through infrastructure projects funded by EC.
Further strategic focus will give to knowledge sharing, harmo-
nization of research and techniques, and fostering translational 
vaccine research. EVI will continue to partner with industry 
and/or public institutions to support the pharmaceutical scale-
up and production of clinical batches for full clinical develop-
ment, through its main activities including communication with 
stakeholders, advocacy and raising funds.
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Key issues
• The European Vaccine Initiative (EVI) was initiated to address the translational gap between promising diseases of poverty vaccine 
candidates and early-phase clinical trials.
• The EVI supports all diseases of poverty vaccine development activities, both financially and technically.
• In the last decade, EVI has contributed to the development of 24 malaria antigens and performed ten clinical trials in Europe and Africa.
• The EVI fosters standardization and harmonization within European vaccine development efforts through several European Commission 
consortia.
• The TRANSVAC consortium stakeholder group, which contains European vaccine R&D groups, funders, regulators and vaccine 
manufacturers, will develop a European road map for sustained vaccine R&D.
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